Recent Updates
Recently added Catalysts

PF-08656795

Phase 1

Overweight and/or Obesity | Small molecule | Metabolic |Pfizer, Inc.|Trials Updated: Oct 15, 2026

PF-08656795 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment150

FDA Designations

No designations recorded

PF-08656795 clinical trials

PF-08656795 · 1 trial · 1 indication

Phase 1 1
NCT07876518A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or ObesityOverweight and/or Obesity
NOT YET_RECRUITING150 Analytics
PHASE1NOT YET_RECRUITING
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
Overweight and/or Obesity
NCT07876518150
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of Treatment Emergent Adverse Events (TEAEs)
Up to 12 weeks after last dose

Secondary Endpoints

Area Under the Curve from Time Zero to to time tau (AUCtau)
0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose
Maximum Observed Concentration (Cmax)
0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
PF-08656795EXPERIMENTALParticipants will receive PF-08656795 once a month or less frequently
PlaceboEXPERIMENTALParticipants will receive placebo once a month or less frequently

Interventions

NameTypeDescription
PlaceboDRUGGiven subcutaneously (under the skin).
PF-08656795DRUGGiven subcutaneously (under the skin).
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersYes

Inclusion: * Body mass index (BMI) ≥25 to ≤40 kg/m2; with stable body weight for ≥3 months prior to screening. * Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension) Exclusion: \- Individuals with clinically significant hematological...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 15, 2026NCT07876518NEW_TRIAL: changed
LOWOct 15, 2026NCT07876518NEW_TRIAL: changed

Explore more on BiopharmaWatch

Pfizer, Inc. (PFE)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track